



Australian Government
Department of Health and Ageing



Australia and New Zealand Horizon Scanning Network

ANZHSN

AN INITIATIVE OF THE NATIONAL, STATE AND
TERRITORY GOVERNMENTS OF AUSTRALIA
AND THE GOVERNMENT OF NEW ZEALAND

Horizon Scanning Technology

Prioritising Summary

NMP22 BladderChek Diagnostic test for bladder cancer

Update: November 2009



© Commonwealth of Australia 2009

ISBN

Publications Approval Number:

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the *Copyright Act 1968*, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Canberra ACT 2600 or posted at <http://www.ag.gov.au/cca>

Electronic copies can be obtained from <http://www.horizonsscanning.gov.au>

Enquiries about the content of the report should be directed to:

HealthPACT Secretariat
Department of Health and Ageing
MDP 106
GPO Box 9848
Canberra ACT 2606
AUSTRALIA

DISCLAIMER: This report is based on information available at the time of research cannot be expected to cover any developments arising from subsequent improvements health technologies. This report is based on a limited literature search and is not a definitive statement on the safety, effectiveness or cost-effectiveness of the health technology covered.

The Commonwealth does not guarantee the accuracy, currency or completeness of the information in this report. This report is not intended to be used as medical advice and intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used therapeutic purposes or as a substitute for a health professional's advice. The Commonwealth does not accept any liability for any injury, loss or damage incurred by use of or reliance the information.

The production of this Horizon scanning prioritising summary was overseen by the Health Policy Advisory Committee on Technology (HealthPACT), a sub-committee of the Medical Services Advisory Committee (MSAC). HealthPACT comprises representatives from departments in all states and territories, the Australia and New Zealand governments; and ASERNIP-S. The Australian Health Ministers' Advisory Council (AHMAC) supports HealthPACT through funding.

This Horizon scanning prioritising summary was prepared by Linda Mundy and Professor Janet Hiller from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Discipline of Public Health, School of Population Health and Clinical Practice, Mail Drop DX 650 545, University of Adelaide, Adelaide, SA, 5005.

PRIORITISING SUMMARY (UPDATE 2009)

REGISTER ID: 000150

NAME OF TECHNOLOGY: NMP22 BLADDERCHEK™

PURPOSE AND TARGET GROUP: DIAGNOSTIC TEST FOR BLADDER CANCER

NOVEMBER 2009 – BACKGROUND

The NMP22® BladderChek® is a point-of-care diagnostic immunochromatographic assay that detects elevated amounts of nuclear matrix protein NMP22, a proteomic marker for cancer. BladderChek® is produced by Inverness Medical Innovations Inc USA and does not require TGA approval for use in Australia. Several other assays using biomarkers other than NMP22 will also be discussed in this update. The United States Food and Drug Administration has approved the use of two markers for the detection of bladder cancer: the BladderChek® assay and the UroVysion (Abbott Molecular) a fluorescence *in situ* hybridisation (FISH) assay (Lotan & Shariat 2008).



The BladderChek® is a small cassette (Figure 1). Patients are asked to provide a fresh urine sample. Samples may be produced “in-office” for immediate processing or posted in the provided container for off-site testing within 24 hours. Four drops of a urine sample are added to the “S” well. The test results should be read 30-50 minutes after sample addition. Two kits are commercially available: one capable of processing a single sample and the other can process 24 samples, including a positive and negative control.

Figure 1 The BladderChek® test cassette (Inverness Medical Innovations Inc 2009)

Positive, negative or invalid test results are indicated by the presence of lines at C or T (Figure 2).




Figure 2 Negative, positive or invalid BladderChek® test results (Inverness Medical Innovations Inc 2009)

NOVEMBER 2009 - SAFETY AND EFFECTIVENESS ISSUES

In the most recent published study, Lotan et al (2009) enrolled 1,502 asymptomatic subjects who were considered to be at high risk of bladder cancer (aged > 50 years, a 10-year or more smoking history or significant workplace exposure in the dye, chemical or petroleum industry. Subjects with a history of urological malignancy or gross haematuria were excluded. All subjects underwent testing with BladderChek[®], however only those subjects with a positive result went on for further testing with cytology (level IV diagnostic evidence). A positive BladderChek[®] result was reported for 85/1502 (5.7%) participants, however only 69 of these elected to undergo cytology. Of these 69 participants, four were found to be positive for carcinoma of the bladder by cytology (PPV = 5.8%). Of the 1,502 enrolled participants, 1,309 (87%) were followed-up for a mean of 12 months (range 0.9 – 25.5 months). At follow-up, two participants who tested negative with BladderChek[®] were found to have developed low grade, non-invasive (Ta) bladder cancer. Of the 85 participants who tested positive with BladderChek[®], 6-month and 12-month follow-up was available in 12 and 58 participants, respectively. No further cancers were detected in this group. In a high-risk, asymptomatic population, BladderChek[®] has a poor positive predictive value and is therefore not a suitable tool for population screening. Identification of higher-risk populations would be necessary for the routine use of this test.

Steiner et al (2008) recruited 183 subjects all with a history of smoking \geq 40 pack-years. Subjects with a history of urological malignancy or had stopped smoking >10 years were excluded. All subjects underwent urinary dipstick testing for haematuria, BladderChek[®] testing, cytology and the UroVysion FISH test. Subjects with at least one positive test were further evaluated with a CT of the upper urinary tract. Cytoscopy was only performed if the urinary dipstick or the BladderChek[®] test returned a positive result but a negative cytology and UroVysion test (level IV diagnostic evidence).

Of the 183 participants, 108 were negative for all tests (59%) but were advised to be re-tested in 12-months time. One subject, who was negative for all tests, was re-tested seven weeks after screening due to macro-haematuria and was found to be positive. Seventy-five patients had at least one positive test and were evaluated further and 18 of these had abnormal histological findings. The urinary dipstick, BladderChek[®], cytology and UroVysion tests detected 9/18 (50%), 1/18 (6%), 7/18 (39%) and 11/18 (61%) of these true positives, respectively. Although the authors reported PPV values, PPV can only be calculated when all participants receive the diagnostic test of interest *and* the reference standard, in this case cytology. BladderChek[®] performed poorly in comparison to other tests, with the *in situ* hybridisation test, UroVysion able to detect the highest number of true positive cases.

Lotan and Shariat (2008) performed a secondary analysis (univariate analyses using logistic regression modelling) of the 2005 study conducted by Grossman et al. The 2005 study examined NMP22 BladderChek™ testing of 1,331 patients at elevated risk for bladder cancer (level II diagnostic evidence). In this study the performance of the NMP22 test was compared with voided urine cytology as an aid to detecting bladder cancer. Grossman et al (2005) reported that cystoscopy detected 79 (6%) patients with bladder cancer and 685 (51%) with one or more benign urological conditions. There was no cystoscopic evidence of urinary tract disease in 567 (43%) patients. BladderChek® was positive (sensitive) in 44 (56%), 95% CI [44, 67], of the 79 patients with cancer, whereas cytology identified 12/76 (16%), 95% CI [7, 24]. The overall positive predictive value¹ (PPV) for the detection of bladder cancer with BladderChek® was 20.3 per cent and the negative predictive value² (NPV) was 96.9 per cent.

Lotan and Shariat (2008) assessed the effect of age, gender, presence of haematuria³ and smoking history on the performance of the BladderChek® assay on these high-risk patients. The overall PPV for men was higher (24.0%) than that for women (13.2%), however the PPV for women increased with age (8.7% for women aged 50-60 years, 23.1% for women aged 70-80 years). The PPV remained relatively stable with age for men, as did the NPV for both males (94.7 - 97.4%) and females (91.2 – 100%). The overall PPV was higher in male smokers (35.4%) compared to non-smokers⁴ (18.4%), however the converse was true for females with smokers having a lower PPV (9.7%) compared to non-smokers (15.6%). The PPV increased markedly in males with haematuria: with no haematuria PPV = 0 %, micro-haematuria PPV = 14.6 % and gross-haematuria PPV = 51.2 %. The PPV was higher again in male smokers with gross-haematuria (70.6%). An increase in PPV in females with haematuria was also noted: no haematuria PPV = 0 %, micro-haematuria PPV = 8.0 % and gross-haematuria PPV = 28.6 %. The PPV of the BladderChek® test improves in patients at a higher risk of bladder cancer and is at its highest in males aged ≥ 65 years who smoke and present with gross-haematuria. It should be noted, however, that all patients presenting with haematuria over the age of 40 years should be evaluated with cytology.

A recent review by Budman et al (2008) summarised the sensitivity and specificity of a number of tests used for the detection and surveillance of bladder cancer (Table 1). Although 85 per cent of bladder cancer patients have macro- or gross-haematuria, fewer than five per cent of patients with haematuria have bladder cancer. Therefore

¹ PPV = the proportion of patients with positive test result who are correctly diagnosed as having the disease.

² NPV = the proportion of patients with negative test result who are correctly diagnosed as **not** having the disease.

³ Blood in the urine.

⁴ The cancer incidence was higher in male smokers (10.7%) than male non-smokers (6.2%) but comparable in female smokers (3.7%) and non-smokers (3.1%)

the haematuria dipstick assay, although low-cost and reproducible, has a poor specificity and PPV. Cytology is widely used and is non-invasive but should be analysed by an experienced pathologist. Although cytology has good specificity it has poor sensitivity as can be seen from the wide range of reported sensitivity values (12-85%). The bladder tumour antigen test or the BTA Stat or Trak tests, which use antibodies to detect elevated levels of the complement factor H-related protein (CFHrp) in urine. CFHrp has been demonstrated to be released by tumour cells. Both tests appear to be more sensitive but less specific than cytology. As previously discussed, the BladderChek[®] and the NMP22 bladder cancer test have variable sensitivity and poor PPVs. Budman et al also discuss spectrum bias associated with these tests due to the arbitrary cut-off values for a positive test (10 U/ml). To illustrate this concept, of 83 patients with NMP22 values between 9 and 11 U/ml, 19 (23%) of patients with a score below 10 U/ml actually had bladder cancer but would have been declared negative and 37 (53%) patients with a score above 10 U/ml were cancer free but would have been declared positive. The ImmunoCyt assays require technical expertise and extensive sample handling and uses monoclonal antibodies to detect antigens originating from tumours. The assays appear to have improved sensitivity compared to cytology. The fluorescent *in situ* hybridisation assay, UroVysion targets genetic sequences associated with bladder cancer. UroVysion is more sensitive but has a slightly lower specificity than cytology. UroVysion has FDA approval. The authors conclude that no assay is sensitive or specific enough to replace cystoscopy for the detection of bladder cancer but may be used for surveillance of patients with transitional cell carcinoma between cystoscopies.

Table 1 Summary of sensitivity and specificity values for tests used for the detection of bladder cancer

Test (number of studies)	Sensitivity range (%)	Specificity range (%)
Cytology (24)	12.2 - 84.6	78.0 - 100
Haematuria dipstick (6)	47.0 - 92.6	51.0 - 84.0
BTA Stat (8)	52.5 - 78.0	69.0 - 87.1
BTA Trak (3)	51.0 - 100.0	72.6 - 100
ImmunoCyt / uCyt+ (6)	63.3 - 84.9 / 81.0 - 89.3	62.0 - 78.1 / 61.0 - 85.9
BladderChek [®] (5)	50.0 - 91.3	45.6 - 87.5
NMP22 Bladder cancer test (11)	49.5 - 84.8	40.0 - 89.8
UroVysion (7)	68.6 - 100	65.0 - 96.0

2009 REFERENCES:

Budman, L. I., Kassouf, W. & Steinberg, J. R. (2008). 'Biomarkers for detection and surveillance of bladder cancer', *Can Urol Assoc J*, 2 (3), 212-221.

Inverness Medical Innovations Inc (2009). *NMP22® BladderChek® Test* [Internet]. Available from: <http://www.matritech.com/bladderchek.php#> [Accessed 14th September].

Lotan, Y., Elias, K. et al (2009). 'Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker', *J Urol*, 182 (1), 52-57; discussion 58.

Lotan, Y. & Shariat, S. F. (2008). 'Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection', *BJU Int*, 101 (11), 1362-1367.

MSAC (2005). *UroVysion fluorescence in situ hybridisation (FISH) assay*, Medical Services Advisory Committee, Canberra. Available from: [http://www.msac.gov.au/internet/msac/publishing.nsf/Content/2CDBC3816FDE8D20CA2575AD0082FD8E/\\$File/1084%20-%20UroVysion%20Report.pdf](http://www.msac.gov.au/internet/msac/publishing.nsf/Content/2CDBC3816FDE8D20CA2575AD0082FD8E/$File/1084%20-%20UroVysion%20Report.pdf)

Steiner, H., Bergmeister, M. et al (2008). 'Early results of bladder-cancer screening in a high-risk population of heavy smokers', *BJU Int*, 102 (3), 291-296.

Zwarthoff, E. C. (2008). 'Detection of tumours of the urinary tract in voided urine', *Scand J Urol Nephrol Suppl*, (218), 147-153.

AUGUST 2007 – UPDATE

AUGUST 2007 – COMPARATORS

Comparators to BladderChek™ include a variety of other tests, both commercial and self-developed, these include: gene specific tests, in-house developed NMP-22 (the marker detected by the BladderChek™ kit) ELISAs, and tests for telomerase markers amongst others.

A combined assay for the tumour markers CYFRA21-1, telomerase and vascular endothelial growth factor (VEGF), showed a very high level of sensitivity compared to cytology, 94 vs 38 per cent in 100 patients who were known to be cancer positive. The patients were diagnosed with bladder transitional cell carcinoma, which was either superficial or invasive. In the testing of 50 patients who were bladder cancer negative but haematuria positive (a common cause of false positives), the specificity of the assays were reported to be 78, 84 88 and 92 per cent for CYFRA21-1, telomerase, VEGF, and cytology, respectively (Bian & Xu 2007).

In a study dividing patients into four groups - primary cancer, histologically confirmed cancer recurrence, post-operative cancer patients who were non-recurrent for six months; and healthy controls, it was found that NMP-22 was an effective marker for bladder cancer diagnosis. The sensitivity was reported to be 52 per cent and the specificity was 95 per cent. Further progression of the disease was linked to higher sensitivity of the NMP-22 assay (Darenkov et al 2006).

Several commercial kits are now available on the market to detect bladder cancer. A review of these kits compared to cytology, the current standard for bladder cancer diagnosis, reported that only UroVysion™ had a satisfactory sensitivity and specificity (80% and 94% respectively). The kits assessed in this review were ImmunoCyt / uCyt+, BTA TRAK, BTA stat, NMP22, NMP22 BladderChek, and UroVysion assays for bladder cancer (Feil & Stenzl 2006).

A PCR based assay testing the promoter hypermethylation of several markers was described by Hoque et al. This assay showed a sensitivity of 82 per cent (95% CI [75, 87]) and a specificity of 96 per cent (95% CI [90, 99]) for bladder cancer detection in 175 bladder cancer patients and 94 healthy subjects (Hoque et al 2006) (level III-3 diagnostic evidence).

A study assessing the diagnostic ability of a RT-PCR assay for the urinary survivin gene in 24 bladder cancer confirmed cases, 50 cases with bladder cancer history, 55 cases with haematuria, and 68 healthy subjects reported an overall sensitivity of 79 per cent and a specificity of 93 per cent. Within each group the sensitivity and specificity did not vary significantly from the overall figure, indicating the test was accurate in all the groups studied.(Kenney et al 2007).

The NMP-22 assay (in house developed) was reported to be superior to both cytology and urinary bladder cancer II (UBC II) assays for detecting the post-operative early recurrence of bladder cancer (Kibar et al 2006). This study included 60 patients with transitional cell carcinoma of the bladder and 30 subjects with unrelated urological diseases. Ten days after the primary cancer was operated upon urine samples were tested by UBC II, NMP-22 and cytology. Versus three month post operative cystoscopy, the NMP-22 assay had the highest sensitivity for early recurrence of cancer 52%, whereas UBC II and cytology sensitivities were reported at 19% and 14% respectively.

A study comparing a multiprobe FISH (fluorescence in situ hybridization) assay with standard urinary cytology for detection of superficial urothelial carcinoma of the bladder found that FISH had a much higher sensitivity (70.3% versus 35.1% for urinary cytology) and a statistically equivalent specificity (94.7% versus 100% for urinary cytology). This study involved 74 patients with superficial urothelial carcinoma, 19 patients with muscle-invasive tumours, and 19 healthy subjects (Marin-Aguilera et al 2007).

The investigation of 113 patients with haematuria for diagnosing bladder cancer reported that BladderChek™ had a sensitivity of 86% and specificity of 98% compared to 57% sensitivity and 97% specificity for urine cytology. This high specificity is a reflection of the exclusion from the study of patients with conditions known to reduce the specificity of the BladderChek™ assay, that is patients with stones, urethral catheters or urinary tract infections (Oehr & Schroeder 2006).

Table 2 Sensitivity and specificity of urine based bladder markers

Bladder cancer marker	Mean sensitivity (range)	Mean specificity (range)
Cytology	48.00% (28%–76.47%)	95.72% (81%–100%)
NMP22	67.49% (31%–91.7%)	74.38% (5.1%–94.3%)
BTA stat	68.71% (52.8%–89%)	73.67% (54%–93%)
BTA TRAK	61.96% (17%–77.5%)	73.59% (50.5%–95%)
Telomerase	72.4% (46%–92%)	87.15% (69%–99%)
Hyaluronic acid and hyaluronidase	94% (91%–100%)	80.93% (70%–88.8%)
Flow cytometry and Quanticyt™ assay	58.08% (45%–72%)	80.62% (70.6%–93%)
Fluorescence in situ hybridization	77% (73%–81%)	98% (96%–100%)
ImmunoCyt™	58.2% (38.5%–86.1%)	78.77% (73%–83.9%)
Cytokeratin 20	82.83% (71%–94.4%)	73.37% (36%–96.7%)
Cytokeratins 8 and 18 (UBC)	60.7% (48.7%–70%)	83.82% (72%–95%)
Lewis X antibody	87.1% (79.8%–94.4%)	61.65% (36.9%–86.4%)
Hemoglobin dipstick	71.2% (47%–92.6%)	67.27% (51%–84%)
CYFRA 21-1	74.15% (69%–79.3%)	91.3% (88.6%–94%)
Survivin	64%	93%

Adapted from (Konety 2006), a review of 111 studies

Table 2 presents a summary of sensitivity and specificity ranges of a variety of tests, designed to detect bladder cancer, as presented in a 2006 review. BladderChek™ was not assessed in this review but the marker that BladderChek™ is based on (NMP22) was reviewed.

AUGUST 2007 - EFFECTIVENESS AND SAFETY ISSUES

Five additional studies were identified examining effectiveness and safety of the BladderChek™ assay. Three of these studies examined use of the assay for diagnosis while the remaining two assessed its value in providing prognostic information.

Kitsukawa compared the BladderChek™ assay to NMP-22 ELISA and urinary cytology and found the BladderChek™ assay was the most sensitive yet the *least* specific of these tests. In 40 patients with confirmed bladder cancer, the sensitivities were 62.5, 55 and 27.5 per cent for BladderChek™, NMP-22 ELISA, and urine cytology, respectively. In 40 subjects *negative* for bladder cancer, the specificities were reported as 87.5, 90 and 100 per cent for BladderChek™, NMP-22 ELISA, and urine cytology, respectively (Kitsukawa et al 2006) (level III-2 diagnostic evidence). In the second diagnostic study involving 51 patients (43 cases with bladder cancer, and 8 cases with upper urothelial cancer) BladderChek™ showed the highest level of sensitivity, mainly due to its much higher sensitivity for lower grade cancers, compared to NMP-22 ELISA and urinary cytology.

The three assays performed similarly for high grade tumours (68.4%, 68.4% and 63.2% sensitivity for BladderChek™, NMP-22 and urine cytology respectively). However, sensitivity differed significantly when testing patients with *low grade* tumours (58.3%, 33.3% and 8.3% respectively). BladderChek™ assay gave false positive results if more than 10^5 erythrocytes and 10^3 white blood cells were present per microlitre of urine (Yokoyama et al 2004) (level III-3 diagnostic evidence). In a diagnostic study involving 43 patients, BladderChek™ was assessed alongside standard urinary cytology against cystoscopy. It was found that the BladderChek™ assay had a greater sensitivity but a lower specificity compared to urinary cytology, 63.6% vs. 36.3% respectively for sensitivity and 62.5% vs. 100% respectively for specificity. All the samples positive by urine cytology were also detected as positive by the BladderChek™ assay. The higher false positive rate for the BladderChek™ assay was attributed to the presence of haematuria, pyuria, or cytolysis or normal urotherium (Minagawa et al 2006) (level IV diagnostic evidence).

A study, involving 2,871 patients, investigating the variability of the NMP-22 assay in the prognostic assessment of patients for either disease progression or recurrence reported there was no satisfactory cut-off level for an indicative level of NMP-22 that would distinguish between these conditions. The manufacturer's cut-off level gave a sensitivity of 57 per cent and a specificity of 81 per cent. Overall the test was more sensitive for latter stage disease vs early stage disease. It was concluded that there was no definitive cut off using this assay but rather a continuum with significant

institutional variation (Shariat et al 2006) (level III-3 prognostic evidence). A second prognostic study which involved monitoring for superficial bladder cell carcinoma in patients after cancer treatment, reported that BladderChek™ had a low sensitivity compared to cystoscopy (28% vs. 100%). The specificity of BladderChek™ was better than cystoscopy at 94 vs. 87 per cent. The authors recommended against using the BladderChek™ assay for follow up of patients with superficial bladder cell carcinoma. In this study BladderChek™ displayed similar sensitivity and specificity to the NMP-22 and cytology assays (Aguilera Tubet et al 2005) (level IV prognostic evidence).

AUGUST 2007 - OTHER ISSUES

In the previous update (May 2006) a study by Grossman was assessed (Grossman et al 2006). Subsequently, criticism of the design and conclusions of this study was reported (Wilson 2006; Eggener & Herr 2006). These critiques focussed on the uneven application of the reference standard, the positive conclusion despite the moderate sensitivity reported, the lesser specificity versus cytology, and the fact that the poor sensitivity of cytology in the Grossman study, versus the sensitivity reported in the literature, may give a favourable bias to the NMP-22 assay.

There are many markers for diagnosis of bladder cancer, either currently being assessed and/or available commercially, which may be of equivalent or better at bladder cancer diagnosis than the BladderChek™ assay (Konety 2006).

AUGUST 2007 – SUMMARY OF FINDINGS

The BladderChek™ assay offers rapid point of care diagnosis of patients being assessed for bladder cancer; giving a moderately sensitive result. It lacks in specificity when compared to the standard, non-invasive test urinary cytology. To overcome the lack of specificity the clinician must exclude several other possible causes of symptoms otherwise BladderChek™ will have a high false positive rate. The fact that other tests and examinations must be concluded before BladderChek™ is accurate undermines its utility as a point of care test.

AUGUST 2007 HEALTHPACT ACTION:

Other tests have better sensitivity and specificity and are available commercially, and many more markers are currently being assessed for future clinical use. Therefore as point-of-care tests for bladder cancer are rapidly evolving and show much promise HealthPACT have recommended that this technology be monitored for more information in 24-months time.

AUGUST 2007 - REFERENCES:

Aguilera Tubet, C., Gutierrez Banos, J. L. et al (2005). '[Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma]', *Actas Urol Esp*, 29 (3), 252-256.

- Bian, W. & Xu, Z. (2007). 'Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma', *Int J Urol*, 14 (2), 108-111.
- Darenkov, S. P., Perlin, D. V. et al (2006). '[Efficacy of detection of specific nuclear protein of matrix 22 in the urine in diagnosis of urinary bladder cancer]', *Urologiia*, (6), 48, 49-51.
- Eggerer, S. & Herr, H. (2006). 'NMP22 and surveillance for recurrent bladder cancer', *JAMA*, 296 (1), 45; author reply 45-46.
- Feil, G. & Stenzl, A. (2006). 'Tumor marker tests in bladder cancer', *Actas Urologicas Espanolas*, 30 (1), 38-45.
- Grossman, H. B., Soloway, M. et al (2006). 'Surveillance for recurrent bladder cancer using a point-of-care proteomic assay', *JAMA*, 295 (3), 299-305.
- Hoque, M. O., Begum, S. et al (2006). 'Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection', *J Natl Cancer Inst*, 98 (14), 996-1004.
- Kenney, D. M., Geschwindt, R. D. et al (2007). 'Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin', *Tumour Biol*, 28 (2), 57-62.
- Kibar, Y., Goktas, S. et al (2006). 'Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder', *Ann Clin Lab Sci*, 36 (1), 31-38.
- Kitsukawa, S., Yamamoto, Y. et al (2006). '[Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer]', *Hinyokika Kyo*, 52 (3), 167-172.
- Konety, B. R. (2006). 'Molecular markers in bladder cancer: A critical appraisal', *Urologic Oncology: Seminars and Original Investigations*, 24 (4 SPEC. ISS.), 326-337.
- Marin-Aguilera, M., Mengual, L. et al (2007). 'Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer', *Cancer Genet Cytogenet*, 173 (2), 131-135.
- Minagawa, T., Nishizawa, S. et al (2006). 'Novel NMP22 quick qualitative analysis (BladderChek NMP22R) for the diagnosis of urothelial tumor', *Japanese Journal of Urology*, 97 (1), 20-26.
- Oehr, P. & Schroeder, A. (2006). 'Utility of the qualitative NMP22(registered trademark)BladderChek(trademark)-test for diagnosis of patients with hematuria and suspected urinary bladder cancer: Results of a medical practice oriented ring-study', *Tumor Diagnostik und Therapie*, 27 (5), 205-210.
- Shariat, S. F., Marberger, M. J. et al (2006). 'Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer', *J Urol*, 176 (3), 919-926; discussion 926.
- Wilson, C. T. (2006). 'NMP22 and surveillance for recurrent bladder cancer', *JAMA*, 296 (1), 44-45; author reply 45-46.
- Yokoyama, T., Sekigawa, R. et al (2004). '[The clinical efficacy of Bladder Chek NMP22 in urothelial cancer]', *Rinsho Byori*, 52 (3), 199-203.

NUMBER OF STUDIES INCLUDED

Total number of studies	
level III-2 diagnostic evidence	1
level III-3 diagnostic evidence	1
level III-3 prognostic evidence	1
level IV diagnostic evidence	2

UPDATE: MAY 2006

MAY 2006 - COMPARATORS

Published literature indicates that fluorescence in situ hybridization (FISH) is emerging as a valid test for bladder cancer surveillance. A critical review of Medline literature indicated that FISH was superior in performance when compared to cytology, and was able to detect cancer before lesions were evident using cystoscopy. Notably the greatest advantage of FISH was the ability to detect high grade urothelial cancer and in particular, carcinoma in situ (Jones 2006).

Svatek et al (2006) investigated the possibility of urinary soluble Fas (sFas) as an effective and independent predictor of bladder cancer recurrence and invasiveness in patients who had a past history of non-muscle invasive bladder transitional cell carcinoma (TCC). This study showed that sFas outperformed NMP22 in the surveillance of patients with a past history of non-muscle invasive bladder TCC.

MAY 2006 UPDATE - SAFETY EFFECTIVENESS AND ISSUES

The gold standard for diagnosing bladder cancer is cystoscopy and biopsy.

Since the initial Prioritising Summary three studies investigating the effectiveness of the NMP22 assay compared to cytologic analysis and cystoscopy have been published. Moonen et al (Moonen et al 2005) described a study in which 106 patients provided a voided urinary specimen prior to cystoscopy or bladder tumour resection (level III-1 diagnostic evidence). The total sample included 28 patients presenting with haematuria, 57 patients in follow-up for superficial bladder cancer and 21 patients who provided a specimen prior to bladder tumour resection. Assessment of NMP22 assay results was performed without knowledge of cytology results.

For patients with haematuria, the sensitivity of both the NMP22 assay and cytology were 100 per cent when compared to cystoscopy, and the specificity was 92 and 100 per cent, respectively. In the superficial bladder cancer group of patients, the sensitivity and specificity of the NMP22 assay was 57 and 90 per cent respectively, compared to 43 and 93 per cent respectively for cytology. The positive predictive value (PPV) and negative predictive value (NPV) for the NMP22 assay were 41 and 95 per cent, respectively. The PPV and NPV were similar for cytology, at 43 and 93 per cent, respectively (Moonen et al 2005).

In addition, there was improvement in the sensitivity of the NMP22 assay as the stage of the tumour progressed. The NMP22 assay was more sensitive than cytology; 40% vs. 33% for stage Ta tumours, 83% vs. 67% for stage T1 and 100% vs. 86% for stages T2-T4. Similarly, the sensitivity of the NMP22 assay also increased as the grade of the tumour increased, however the sensitivity of cytology assay was greater at a lower grade of tumour. For grade 1 tumours the sensitivity of the NMP22 assay and cytology were 29 per cent and 43 per cent respectively, 89 per cent and 56 per cent respectively for grade 2 tumours and both 62 per cent for grade 3 tumours.

A prospective study was conducted whereby 131 patients with a previous history of superficial bladder cancer, on follow-up, were enrolled (level III-1 diagnostic evidence) (Kumar et al 2006). A voided urine specimen was collected prior to

cystoscopy and used to perform cytological analysis and the NMP22 assay. Findings from biopsies taken during cystoscopy were treated as a gold standard. All observers interpreting the test results were blinded to the results of the other tests.

Of the 131 patients in the study, 46 patients tested positive for recurrence by biopsy. Of these 46 patients, 39 were positive for the NMP22 assay and 19 were positive for cytology. The sensitivity and specificity of the NMP22 assay was 85 and 78 per cent, respectively (PPV = 67%, NPV = 90%). In comparison, the sensitivity and specificity of cytology was 41 and 96 per cent, respectively (PPV = 86%, NPV = 75%). The sensitivity of the NMP22 assay was greater than that of cytology particularly for low T stage malignancies as demonstrated in Table 3. The table also demonstrates that the sensitivity of the NMP22 assay was significantly greater than that of cytology in detecting lower grade tumours.

When the results of both the NMP22 assay and cytology were combined, 42 of the 46 tumours detected by cystoscopy were identified, which gave an overall sensitivity of 91 per cent (Kumar et al 2006).

Table 3 Sensitivity according to T stage and grade of tumour

N=46	NMP22 Test (%)	Urine cytology (%)	P-value
Stage			
Ta (n=21)	76.2 (16/21)	14.3 (3/21)	0.0002
T1 (n=17)	88.2 (15/17)	47 (8/17)	0.003
T2 or higher	100 (8/8)	100 (8/8)	
Grade			
G1 (n=11)	81.8 (9/11)	18.8 (2/11)	0.009
G2 (n=22)	81 (18/22)	27.2 (6/22)	0.0009
G3 (N=13)	92.3 (12/13)	84.6 (11/13)	0.54

A cross-sectional study investigated the use of NMP22 BladderChek in improving the detection of bladder cancer (Grossman et al 2006) (level II diagnostic evidence). Consecutive patients were recruited (n=668) across 23 clinical sites. Each patient submitted a voided urine sample before undergoing cystoscopy. The urine sample was sent for routine cytologic examination as well as being analysed for NMP22 protein by clinic staff. Physicians who performed the cystoscopies were blinded to the NMP22 results and staff that performed the NMP22 assays were blinded to cystoscopy results. Patients were classified as positive for bladder cancer if one or more tumours were observed during cystoscopy and, if removed, were considered malignant upon pathological examination.

Initially, cystoscopy detected 94/103 (91%) cancers, the remaining 9 were detected upon repeat evaluation as a result of continued suspicion or close follow-up. The NMP22 assay detected 43/94 (45.7%) tumours initially detected and 8/9 (89%) malignancies detected upon repeated evaluation (49.5%). Cytological results were available for 98/103 malignant samples detected and 552/565 samples without cancer. Of the malignant samples, cytology found 12/98 (12.2%) with cancerous or dysplastic cells. Combining the NMP22 test with cystoscopy improved the overall sensitivity to from 91 to 99 per cent, a difference that was statistically significantly ($p = 0.005$). In comparison, the combination of cytology with cystoscopy increased the overall

sensitivity to 94 per cent, a difference that was not statistically significant ($p = 0.06$). The positive predictive value of the NMP22 assay and cytology were very similar at 42 and 41 per cent, respectively.

Similarly, the specificities of cytology and the NMP22 assay were compared. Cytology proved to be significantly more specific than NMP22 assay at 97 and 87 per cent, respectively ($p < 0.001$). The NPV for the NMP22 assay was 91 per cent and 86 per cent for cytologic analysis (Grossman et al 2006).

MAY 2006 - RECOMMENDATION:

Voided cytology is often utilised as the first step in the diagnosis of bladder cancer, before invasive procedures such as cystoscopy and biopsy. The NMP22 assay had similar overall sensitivity and specificity values as cytology, however the sensitivity of the NMP22 assay was superior in patients with low grade and low stage tumours. NMP22 *combined* with cytology gave *increased* sensitivity and specificity. Studies reported conflicting positive predictive values for NMP22 (41-67%), which may result in a high number of patients undergoing an unnecessary invasive procedure. However, all studies reported good negative predictive values (90-93%) indicating that a high proportion of individuals testing negative do not have bladder cancer. The NMP22 assay is easy to use, non-invasive and provides a rapid result for the clinician. New non-invasive techniques (FISH and sFas) should also be investigated. Based on the good quality evidence it is therefore recommended this technology be monitored for further information in 12-months time.

MAY 2006 - REFERENCES:

- Grossman, H. B., Soloway, M. et al. (2006). 'Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.' *Journal of the American Medical Association*, 295(3), 299-305.
- Jones, J. S. (2006). 'DNA-based molecular cytology for bladder cancer surveillance.' *Urology*, 67(3 Suppl 1), 35-45; discussion 45-7.
- Kumar, A., Kumar, R. et al. (2006). 'Comparison of NMP22 BladderChek Test and Urine Cytology for the Detection of Recurrent Bladder Cancer.' *Japanese Journal of Clinical Oncology*, 36(3), 172-5.
- Moonen, P. M., Kiemeny, L. A. et al. (2005). 'Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.' *European Urology*, 48(6), 951-6; discussion 956.
- Svatek, R. S., Herman, M. P. et al. (2006). 'Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer.' *Cancer*, 106(8), 1701-7.

LIST OF STUDIES INCLUDED

Total number of studies	
Level II diagnostic evidence	1
Level III-1 diagnostic evidence	2

PRIORITISING SUMMARY (2005)

REGISTER ID: 000150
NAME OF TECHNOLOGY: NMP22 BLADDERCHEK™
PURPOSE AND TARGET GROUP: DIAGNOSTIC TEST FOR BLADDER CANCER

STAGE OF DEVELOPMENT (IN AUSTRALIA):

- | | |
|---|---|
| <input checked="" type="checkbox"/> Yet to emerge | <input type="checkbox"/> Established |
| <input type="checkbox"/> Experimental | <input type="checkbox"/> Established <i>but</i> changed indication or modification of technique |
| <input type="checkbox"/> Investigational | <input type="checkbox"/> Should be taken out of use |
| <input type="checkbox"/> Nearly established | |

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION APPROVAL

- | | |
|--|-------------|
| <input type="checkbox"/> Yes | ARTG number |
| <input type="checkbox"/> No | |
| <input checked="" type="checkbox"/> Not applicable | |

INTERNATIONAL UTILISATION:

COUNTRY	LEVEL OF USE		
	Trials Underway or Completed	Limited Use	Widely Diffused
United States	✓		

IMPACT SUMMARY 2005:

Matritech Inc. has developed the point-of-care diagnostic test, NMP22 BladderChek™ for the detection of bladder cancer. The test was approved in the United States in July 2002, and is not yet available in Australia.

BACKGROUND 2005

The majority of cancers of the bladder start in the layer of cells which form the lining (urothelium) of the bladder. These are termed transitional cell or urothelial cell cancers (American Society of Clinical Oncology 2005). The most common clinical presentation is blood in the urine (haematuria). Haematuria is usually painless and the blood may be visible to the naked eye or microscopic. The diagnosis of bladder cancer may be delayed due to intermittent bleeding or may be attributed to other causes such as urinary tract infection or the presence of anticoagulant medications (American Society of Clinical Oncology 2005).

Patients with suspected bladder cancer initially undergo voided urine cytology. A Pap smear is prepared from transitional cells which have sloughed off the urinary tract into the urine. This technique requires intact cells for examination (Grossman et al 2005). If urinary cytology is positive, then transitional cell cancer of the urothelium is almost

certainly present (high positive predictive value). However, cytologic examinations may be negative in up to half of all patients with bladder cancer; therefore, a negative study does not rule out bladder cancer (low negative predictive value). Voided urine cytology is frequently used as an adjunct to the gold standard test of cystoscopy with biopsy (Grossman et al 2005).

The NMP22 BladderChek™ test is a point-of-care immunochromatographic assay that detects elevated amounts of nuclear matrix protein NMP22, a proteomic marker for cancer. Measuring levels of NMP22 for the detection of bladder cancer has been established in different patient groups, including those with confirmed bladder cancer, patients post-transurethral resection of bladder and in conjunction with standard urine cytology and cystoscopy (Carpinito et al, 1996, Soloway et al, 1996, Sawczuk et al, 2000 and Shariat et al, 2004).

The BladderChek™ is the only point-of-care test approved in the United States (Matritech 2005). The Matritech NMP22 BladderChek™ test is indicated for professional and prescription home use as an aid in monitoring bladder cancer patients, in conjunction with standard diagnostic procedures (United States Food and Drug Administration 2005).

CLINICAL NEED AND BURDEN OF DISEASE 2005

Bladder cancer occurs most commonly in people between 50 and 70 years of age. It is twice as common in men as in women (American Society of Clinical Oncology 2005). The incidence of bladder cancer is higher in people exposed to carcinogens in their occupation or environment and significantly higher in smokers.

In 2001 there were 2,954 new cases of bladder cancer in the Australian population, representing a crude rate of 15.2 per 100,000. There was a higher incidence in males (24 per 100,000) compared to females (7 per 100,000), (AIHW 2005a).

In the year 2002-03 there were 15,672 hospitalisations for a principal diagnosis (C67) of malignant neoplasm of bladder (AIHW 2005b).

DIFFUSION 2005

The NMP22 BladderChek™ is not currently available in Australia. In the United States, the cost of using the test is almost half the cost of standard voided urine cytology tests. Given that this test is for point-of-care testing, it is likely that general practitioners and clinicians in hospital settings would incorporate its use in conjunction with cystoscopy. However, at this point it is unclear whether this has occurred in the United States. If further studies found that the NMP22BladderChek™ was better at detecting cancers than those missed by voided cytology (standard urine test) and cystoscopy (reference standard for detection), the test would receive a rapid uptake.

COMPARATORS 2005

A combination of methods is used for the diagnosis of bladder cancer. Voided cytology is the first diagnostic test used in assessing patients for bladder cancer before proceeding to further, invasive tests. The gold standard test is cystoscopy and biopsy. This procedure, performed under local anaesthetic, involves inserting a small,

flexible, fibre-optic telescope (cystoscope) into the urethra to view the whole lining of the bladder and urethra. If abnormal tissue is observed, a general anaesthetic is administered and biopsies of the abnormal cells from the inside of the bladder, or the lining of the bladder are taken for pathologic examination (American Society of Clinical Oncology 2005).

An intravenous urogram or pyelogram are further diagnostic tools employed in evaluating the urinary tract. This involves the injection of radioactive dye into a vein that can be viewed on an x-ray screen for any abnormalities in the kidneys, bladder and the rest of the urinary system.

Other non-invasive urine tests that measure NMP22 levels are not approved for point-of-care use and require laboratory analysis (Grossman et al 2005).

EFFECTIVENESS AND SAFETY ISSUES - APRIL 2005

A multi-site study (level II diagnostic evidence) examined NMP22 BladderChek™ testing of 1,331 patients at elevated risk for bladder cancer (Grossman et al 2005). The performance of the NMP22 test was compared with voided urine cytology as an aid to detecting bladder cancer. Cystoscopy with biopsy was used as the reference standard. One of the sites included 26 patients with cancers other than bladder cancer. All patients with risk factors or symptoms of bladder cancer underwent testing with both the BladderChek™ and standard urine cytology before undergoing cystoscopy. All physicians and technicians were blinded to the BladderChek™, standard urine cytology and cystoscopy results.

Cystoscopy detected 79/1,331 (6%) patients with bladder cancer, 685/1,331 (51%) had 1 or more benign urological conditions and 567/1331 (43%) had no cystoscopic evidence of urinary tract disease. Of the 79 patients with cancer, 72 cancers were surgically removed and seven (labelled TX) were not excised. The BladderChek™ test was positive (sensitive) in 44 (56%), 95% CI [44, 67], of the 79 patients with cancer, whereas cytology identified 12/76 (16%), 95% CI [7, 24].

Of the cancers with pathological staging data, 62 were superficial and 10 were muscle invasive. Pathological determination of grade was available for 70 of the 72 removed tumours. Of these, 27 were classified low grade, 18 were moderate and 25 were high grade. A total of 27 cancers were muscle invasive and/or high grade. Table 4 provides the results of the sensitivity of BladderChek™ and voided cytology by stage and grade of cancer.

Of 79 confirmed malignancies, 10 were muscle invasive. The BladderChek™ identified four of the malignancies missed during cystoscopy. Initial cystoscopy detected 6 (60%) of these malignancies whereas the NMP22 test identified 9 (90%) with elevated levels of the protein marker. Voided cytology was positive in only 2 (22%) of the 9 patients with muscle-invasive disease for whom test results were available. The BladderChek™ was also positive for a patient diagnosed with carcinoma *in situ* after an initial negative cystoscopic report.

This study reports that the BladderChek™ was more accurate than urine cytology in detecting both aggressive malignancies (high grade) (74% vs. 39%) and medium or low grade malignancies (47% vs. 5%).

Table 4 Sensitivity of BladderChek™ Assay and Voided Cytology by Stage and Grade of Cancer

Stage	BladderChek™		Voided Cytology	
	No. with Positive Test Result/Total No. with bladder cancer	Sensitivity % (95% CI)	No. with Positive Test Result/Total No. with bladder cancer	Sensitivity % (95% CI)
Ta	14/30	46.7 (28.3, 65.7)	2/28	7.1 (1.0, 23.5)
Tis	4/5	80.0 (28.4, 99.5)	3/5	60.0 (14.7, 94.7)
T1 #	13/27	48.2 (28.7, 68.1)	5/27	18.5 (6.3, 38.1)
T2, T2a	6/6	100 (54.1, 100)	2/6	33.3 (4.3, 77.7)
T3a, T3b*	3/4	75.0 (19.4, 99.4)	0/3	0 (0, 70.8)
TX**	4/7	57.1 (18.4, 90.01)	0/7	0 (0, 41.0)
Non-invasive: Ta-T1	31/62	50.0 (37.0, 63.0)	10/60	16.7 (8.3, 28.5)
Muscle Invasive: T2 –T3	9/10	90.0 (55.5, 99.8)	2/9	22.2 (2.8, 60.0)
Grade				
Well differentiated	13/27	48.2 (28.7, 68.1)	0/25	0 (0, 13.7)
Moderately differentiated	9/18	50.0 (26.0, 74.0)	3/18	16.7 (3.6, 41.4)
Poorly differentiated	18/25	72.0 (50.6, 87.9)	9/24	37.5 (18.8, 59.4)
GX	4/9	44.4 (13.7, 78.8)	0/9	0 (0, 33.6)

Ta, Tis, T1 were classified superficial, *T2 –T3 were classified aggressive, **TX – 7 tumours seen on cystoscopy but not excised

COST IMPACT 2005

The current MBS fees for item numbers 36836, (cystoscopy with biopsy) and 73045 (urine cytology) are \$195.05 and \$48.95 respectively (Medicare Benefits Schedule 2005). There were 1349 cystoscopy procedures performed between July 2003 and June 2004 and a total Medicare contribution of \$160,777 (Health Insurance Commission 2005).

The average cost of voided cytology in the United States is approximately \$US 56 compared to a cost of \$US 24 for the BladderChek™ test (Grossman 2005).

ETHICAL, CULTURAL OR RELIGIOUS CONSIDERATIONS 2005

No issues were identified/raised in the sources examined.

OTHER ISSUES 2005

It would be useful to assess the impact of using the NMP22 BladderChek™ test on survival of patients with bladder cancer. There is no study to date that assesses the ability of the test to detect cancers at an early stage or earlier than the standard diagnostic procedures.

RECOMMENDATION - APRIL 2005:

There has been only one study published on the effectiveness of the NMP22 BladderChek™ at the time of writing this summary. However, given it is a point-of-care service the uptake may be rapid. It is therefore recommended that this technology be monitored for further information in 12 months time.

REFERENCES - APRIL 2005:

AIHW (2005a) *Interactive Cancer Data*. [Internet] Available from: <http://www.aihw.gov.au/cognos/cgi-bin/ppdscgi.exe?DC=Q&E=/Cancer/cancerageratesv7>

[Accessed April 06, 2005].

AIHW (2005b) *Interactive national hospital morbidity data*. [Internet] Available from:

<http://www.aihw.gov.au/cognos/cgi-in/ppdscgi.exe?DC=Q&E=/AHS/principaldiagnosis0203>

[Accessed April 06, 2005].

American Society of Clinical Oncology (2005) *People Living With Cancer - Cancer Page – Bladder Cancer - Risk Factors and Prevention*: [Internet] Available from:

http://www.plwc.org/plwc/MainConstructor/1,1744,_04-0018-00_12-001042-00_17-001029-00_21-008,00.asp [Accessed April 20, 2005].

H. B. Grossman, E. Messing, M. Soloway, K. Tomera, G. Katz, Y. Berger and Y. Shen, *JAMA*, 2005, **293**, 810-816.

SEARCH CRITERIA TO BE USED:

Bladder Neoplasms/ urine

Carcinoma, Transitional Cell/ urine

Neoplasm Recurrence, Local/ diagnosis/ urine

Nuclear Proteins/ urine

Tumor Markers, Biological/ urine